Neon Therapeutics (NASDAQ:NTGN) PT Set at $21.00 by Mizuho

Mizuho set a $21.00 price target on Neon Therapeutics (NASDAQ:NTGN) in a research note released on Friday, TipRanks reports. The firm currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on NTGN. Zacks Investment Research upgraded shares of Neon Therapeutics from a hold rating to a buy rating and set a $6.00 target price on the stock in a research note on Thursday, March 14th. Berenberg Bank began coverage on shares of Neon Therapeutics in a research note on Wednesday, March 27th. They set a buy rating and a $15.00 target price on the stock. Finally, HC Wainwright began coverage on shares of Neon Therapeutics in a research note on Thursday, May 30th. They set a buy rating and a $10.00 target price on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Neon Therapeutics currently has an average rating of Buy and a consensus target price of $16.94.

Shares of Neon Therapeutics stock opened at $4.64 on Friday. The company has a market cap of $131.46 million and a PE ratio of -0.84. The stock has a 50-day moving average price of $5.15. Neon Therapeutics has a 1 year low of $4.20 and a 1 year high of $16.23. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.09.

Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.03). Research analysts anticipate that Neon Therapeutics will post -2.67 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC lifted its stake in Neon Therapeutics by 1.1% during the 4th quarter. FMR LLC now owns 2,079,669 shares of the company’s stock valued at $10,461,000 after acquiring an additional 23,075 shares during the period. Hillhouse Capital Advisors Ltd. bought a new position in shares of Neon Therapeutics in the 4th quarter worth approximately $1,572,000. BlackRock Inc. lifted its stake in shares of Neon Therapeutics by 12.0% in the 4th quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock worth $1,548,000 after purchasing an additional 32,943 shares during the period. Vanguard Group Inc. lifted its stake in shares of Neon Therapeutics by 215.9% in the 3rd quarter. Vanguard Group Inc. now owns 197,414 shares of the company’s stock worth $1,686,000 after purchasing an additional 134,914 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Neon Therapeutics by 68.9% in the 4th quarter. Northern Trust Corp now owns 88,678 shares of the company’s stock worth $446,000 after purchasing an additional 36,170 shares during the period. Institutional investors and hedge funds own 69.57% of the company’s stock.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: What are the Benefits of Index Funds?

Analyst Recommendations for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.